Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Active, not recruiting
National Cancer Institute (NCI)
Phase 1/Phase 2
This partially randomized phase I/II trial studies the side effects and the best dose of
cediranib maleate and olaparib and to see how well cediranib maleate and olaparib work
compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or
triple-negative breast cancer that has returned after a period of improvement. Cediranib
maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib
may stop cancer cells from growing abnormally. The combination of cediranib maleate and
olaparib may help to keep cancer from growing.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.